Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies

Journal of Experimental Medicine

Volumn 211, Issue 7, 2014, Pages 1433-1448

  Madireddi, Shravan ^a   Eun, So Young ^a   Lee, Seung Woo ^a   Nemčovičová, Ivana ^a   Mehta, Amit Kumar ^a   Zajonc, Dirk M ^a   Nishi, Nozomu ^b   Niki, Toshiro ^b,c   Hirashima, Mitsuomi ^b,c   Croft, Michael ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b KAGAWA UNIVERSITY   (Japan)

^c GalPharma Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD137 ANTIBODY; ECALECTIN; MUCIN 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY COMBINING SITE; ARTICLE; ASTHMA; BINDING SITE; CELL MEMBRANE; CONTROLLED STUDY; DENDRITIC CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HOMEOSTASIS; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES; ANTIGENS, CD137; AUTOIMMUNE DISEASES; GALECTINS; HUMANS; HYPERSENSITIVITY; MICE; MICE, KNOCKOUT; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84903771223     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20132687     Document Type: Article

References (59)

1. Arikawa, T., K. Watanabe, M. Seki, A. Matsukawa, S. Oomizu, K.M. Sakata, A. Sakata, M. Ueno, N. Saita, T. Niki, et al. 2009. Galectin-9 ameliorates immune complex-induced arthritis by regulating FcγR expression on macrophages. Clin. Immunol. 133:382-392. http://dx.doi.org/10.1016/j.clim.2009.09.004
2. Ascierto, P.A., E. Simeone, M. Sznol, Y.X. Fu, and I. Melero. 2010. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37:508-516. http://dx.doi.org/10.1053/j.seminoncol.2010.09.008
3. Bi, S., P.W. Hong, B. Lee, and L.G. Baum. 2011. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc. Natl. Acad. Sci. USA. 108:10650-10655. http://dx.doi.org/10.1073/pnas.1017954108
4. Bodmer, J.L., P. Schneider, and J. Tschopp. 2002. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27:19-26. http://dx.doi .org/10.1016/S0968-0004(01)01995-8
5. Bossen, C., K. Ingold, A. Tardivel, J.L. Bodmer, O. Gaide, S. Hertig, C. Ambrose, J. Tschopp, and P. Schneider. 2006. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 281:13964-13971. http://dx.doi.org/10.1074/jbc.M601553200
6. Bulliard, Y., R. Jolicoeur, M. Windman, S.M. Rue, S. Ettenberg, D.A. Knee, N.S. Wilson, G. Dranoff, and J.L. Brogdon. 2013. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210:1685-1693. http://dx.doi.org/10.1084/jem.20130573
7. Chan, F.K. 2007. Three is better than one: Pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine. 37:101-107. http://dx.doi.org/10.1016/j.cyto.2007.03.005
8. Chan, F.K., H.J. Chun, L. Zheng, R.M. Siegel, K.L. Bui, and M.J. Lenardo. 2000. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 288:2351-2354. http://dx.doi .org/10.1126/science.288.5475.2351
9. Chattopadhyay, K., U.A. Ramagopal, A. Mukhopadhaya, V.N. Malashkevich, T.P. Dilorenzo, M. Brenowitz, S.G. Nathenson, and S.C. Almo. 2007. Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function. Proc. Natl. Acad. Sci. USA. 104:19452-19457. http://dx.doi.org/10.1073/pnas.0709264104
10. Chattopadhyay, K., E. Lazar-Molnar, Q. Yan, R. Rubinstein, C. Zhan, V. Vigdorovich, U.A. Ramagopal, J. Bonanno, S.G. Nathenson, and S.C. Almo. 2009. Sequence, structure, function, immunity: structural genomics of costimulation. Immunol. Rev. 229:356-386. http://dx.doi.org/10.1111/j.1600-065X.2009.00778.x
11. Choi, B.K., T. Asai, D.S. Vinay, Y.H. Kim, and B.S. Kwon. 2006. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine. 34: 233-242. http://dx.doi.org/10.1016/j.cyto.2006.04.008
12. Chou, F.C., S.J. Shieh, and H.K. Sytwu. 2009. Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. Eur. J. Immunol. 39:2403-2411. http://dx.doi.org/10.1002/eji.200839177
13. Compaan, D.M., and S.G. Hymowitz. 2006. The crystal structure of the costimulatory OX40-OX40L complex. Structure. 14:1321-1330. http://dx.doi.org/10.1016/j.str.2006.06.015
14. Croft, M., C.A. Benedict, and C.F. Ware. 2013. Clinical targeting of the TNF and TNFR superfamilies. Nat. Rev. Drug Discov. 12:147-168. http://dx.doi.org/10.1038/nrd3930
15. Earl, L.A., S. Bi, and L.G. Baum. 2011. Galectin multimerization and lattice formation are regulated by linker region structure. Glycobiology. 21:6-12. http://dx.doi.org/10.1093/glycob/cwq144
16. Foell, J., S. Strahotin, S.P. O'Neil, M.M. McCausland, C. Suwyn, M. Haber, P.N. Chander, A.S. Bapat, X.J. Yan, N. Chiorazzi, et al. 2003. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB × NZW F1 mice. J. Clin. Invest. 111:1505-1518. http://dx.doi.org/10.1172/JCI200317662
17. Fulcher, J.A., M.H. Chang, S. Wang, T. Almazan, S.T. Hashimi, A.U. Eriksson, X. Wen, M. Pang, L.G. Baum, R.R. Singh, and B. Lee. 2009. Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J. Biol. Chem. 284:26860-26870. http://dx.doi.org/10.1074/jbc.M109.037507
18. Golden-Mason, L., R.H. McMahan, M. Strong, R. Reisdorph, S. Mahaffey, B.E. Palmer, L. Cheng, C. Kulesza, M. Hirashima, T. Niki, and H.R. Rosen. 2013. Galectin-9 functionally impairs natural killer cells in humans and mice. J. Virol. 87:4835-4845. http://dx.doi.org/10.1128/JVI.01085-12
19. Grigorian, A., S. Torossian, and M. Demetriou. 2009. T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol. Rev. 230:232-246. http://dx.doi.org/10.1111/j.1600-065X.2009.00796.x
20. Hirabayashi, J., T. Hashidate, Y. Arata, N. Nishi, T. Nakamura, M. Hirashima, T. Urashima, T. Oka, M. Futai, W.E. Muller, et al. 2002. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim. Biophys. Acta. 1572:232-254. http://dx.doi.org/10.1016/S0304-4165(02)00311-2
21. Katoh, S., N. Ishii, A. Nobumoto, K. Takeshita, S.Y. Dai, R. Shinonaga, T. Niki, N. Nishi, A. Tominaga, A. Yamauchi, and M. Hirashima. 2007. Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am. J. Respir. Crit. Care Med. 176:27-35.
22. Kim, Y.H., B.K. Choi, S.M. Shin, C.H. Kim, H.S. Oh, S.H. Park, D.G. Lee, M.J. Lee, K.H. Kim, D.S. Vinay, and B.S. Kwon. 2011. 4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells. J. Immunol. 187:1120-1128. http://dx.doi.org/10.4049/jimmunol.1002681
23. Kwon, B.S., and S.M. Weissman. 1989. cDNA sequences of two inducible T-cell genes. Proc. Natl. Acad. Sci. USA. 86:1963-1967. http://dx.doi.org/10.1073/pnas.86.6.1963
24. Kwon, B.S., C.A. Kozak, K.K. Kim, and R.T. Pickard. 1994. Genomic organization and chromosomal localization of the T-cell antigen 4-1BB. J. Immunol. 152:2256-2262.
25. Lee, S.W., and M. Croft. 2009. 4-1BB as a therapeutic target for human disease. Adv. Exp. Med. Biol. 647:120-129. http://dx.doi.org/10.1007/978-0-387-89520-8_8
26. Lee, S.W., Y. Park, S.Y. Eun, S. Madireddi, H. Cheroutre, and M. Croft. 2012. Cutting edge: 4-1BB controls regulatory activity in dendritic cells through promoting optimal expression of retinal dehydrogenase. J. Immunol. 189: 2697-2701. http://dx.doi.org/10.4049/jimmunol.1201248
27. Loo, D.T., N.J. Chalupny, J. Bajorath, W.W. Shuford, R.S. Mittler, and A. Aruffo. 1997. Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB. J. Biol. Chem. 272:6448-6456. http://dx.doi.org/10.1074/jbc.272.10.6448
28. Matsumoto, R., H. Matsumoto, M. Seki, M. Hata, Y. Asano, S. Kanegasaki, R.L. Stevens, and M. Hirashima. 1998. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 273:16976-16984. http://dx.doi.org/10.1074/jbc.273.27.16976
29. Nagae, M., N. Nishi, T. Murata, T. Usui, T. Nakamura, S. Wakatsuki, and R. Kato. 2006. Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. J. Biol. Chem. 281:35884-35893. http://dx.doi.org/10.1074/jbc.M606648200
30. Naismith, J.H., and S.R. Sprang. 1998. Modularity in the TNF-receptor family. Trends Biochem. Sci. 23:74-79. http://dx.doi.org/10.1016/S0968-0004(97)01164-X
31. Nonaka, Y., T. Ogawa, S. Oomizu, S. Nakakita, N. Nishi, S. Kamitori, M. Hirashima, and T. Nakamura. 2013. Self-association of the galectin-9 C-terminal domain via the opposite surface of the sugar-binding site. J. Biochem. 153:463-471. http://dx.doi.org/10.1093/jb/mvt009
32. Ohtsubo, K., S. Takamatsu, M.T. Minowa, A. Yoshida, M. Takeuchi, and J.D. Marth. 2005. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell. 123:1307-1321. http://dx.doi.org/10.1016/j.cell.2005.09.041
33. Oomizu, S., T. Arikawa, T. Niki, T. Kadowaki, M. Ueno, N. Nishi, A. Yamauchi, and M. Hirashima. 2012. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin. Immunol. 143:51-58. http://dx.doi.org/10.1016/j.clim.2012.01.004
34. Pace, K.E., C. Lee, P.L. Stewart, and L.G. Baum. 1999. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J. Immunol. 163:3801-3811.
35. Polte, T., J. Foell, C. Werner, H.G. Hoymann, A. Braun, S. Burdach, R.S. Mittler, and G. Hansen. 2006. CD137-mediated immunotherapy for allergic asthma. J. Clin. Invest. 116:1025-1036. http://dx.doi.org/10.1172/JCI23792
36. Rabinovich, G.A., and M.A. Toscano. 2009. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9:338-352. http://dx.doi.org/10.1038/nri2536
37. Rabinovich, G.A., M.A. Toscano, S.S. Jackson, and G.R. Vasta. 2007. Functions of cell surface galectin-glycoprotein lattices. Curr. Opin. Struct. Biol. 17:513-520. http://dx.doi.org/10.1016/j.sbi.2007.09.002
38. Rabu, C., A. Quéméner, Y. Jacques, K. Echasserieau, P. Vusio, and F. Lang. 2005. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J. Biol. Chem. 280:41472-41481. http://dx.doi.org/10.1074/jbc.M506881200
39. Salek-Ardakani, S., and M. Croft. 2010. Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity. J. Interferon Cytokine Res. 30:205-218. http://dx.doi.org/10.1089/jir.2010.0026
40. Sato, M., N. Nishi, H. Shoji, M. Seki, T. Hashidate, J. Hirabayashi, K. Kasai Ki, Y. Hata, S. Suzuki, M. Hirashima, and T. Nakamura. 2002. Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. Glycobiology. 12:191-197. http://dx.doi.org/10.1093/glycob/12.3.191
41. Schabowsky, R.H., K.G. Elpek, S. Madireddi, R.K. Sharma, E.S. Yolcu, L. Bandura-Morgan, R. Miller, K.J. MacLeod, R.S. Mittler, and H. Shirwan. 2009. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine. 28:512-522. http://dx.doi.org/10.1016/j.vaccine.2009.09.127
42. Seki, M., K.M. Sakata, S. Oomizu, T. Arikawa, A. Sakata, M. Ueno, A. Nobumoto, T. Niki, N. Saita, K. Ito, et al. 2007. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum. 56:3968-3976. http://dx.doi.org/10.1002/art.23076
43. Seki, M., S. Oomizu, K.M. Sakata, A. Sakata, T. Arikawa, K. Watanabe, K. Ito, K. Takeshita, T. Niki, N. Saita, et al. 2008. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol. 127:78-88. http://dx.doi.org/10.1016/j.clim.2008.01.006
44. Seo, S.K., J.H. Choi, Y.H. Kim, W.J. Kang, H.Y. Park, J.H. Suh, B.K. Choi, D.S. Vinay, and B.S. Kwon. 2004. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med. 10:1088-1094. http://dx.doi.org/10.1038/nm1107
45. Shuford, W.W., K. Klussman, D.D. Tritchler, D.T. Loo, J. Chalupny, A.W. Siadak, T.J. Brown, J. Emswiler, H. Raecho, C.P. Larsen, et al. 1997. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186:47-55. http://dx.doi.org/10.1084/jem.186.1.47
46. Siegel, R.M., J.K. Frederiksen, D.A. Zacharias, F.K. Chan, M. Johnson, D. Lynch, R.Y. Tsien, and M.J. Lenardo. 2000. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science. 288:2354-2357. http://dx.doi.org/10.1126/science.288.5475.2354
47. Snell, L.M., G.H. Lin, A.J. McPherson, T.J. Moraes, and T.H. Watts. 2011. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol. Rev. 244:197-217. http://dx.doi.org/10.1111/j.1600-065X.2011.01063.x
48. So, T., S.W. Lee, and M. Croft. 2008. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 19:253-262. http://dx.doi.org/10.1016/j.cytogfr.2008.04.003
49. Su, E.W., S. Bi, and L.P. Kane. 2011. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology. 21:1258-1265. http://dx.doi .org/10.1093/glycob/cwq214
50. Sun, Y., X. Lin, H.M. Chen, Q. Wu, S.K. Subudhi, L. Chen, and Y.X. Fu. 2002. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168:1457-1465. http://dx.doi.org/10.4049/jimmunol.168.3.1457
51. Türeci, O., H. Schmitt, N. Fadle, M. Pfreundschuh, and U. Sahin. 1997. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J. Biol. Chem. 272:6416-6422. http://dx.doi.org/10.1074/jbc.272.10.6416
52. Vaitaitis, G.M., and D.H. Wagner Jr. 2012. Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity. PLoS ONE. 7:e38708. http://dx.doi.org/10.1371/journal.pone.0038708
53. Vinay, D.S., and B.S. Kwon. 2012. Immunotherapy of cancer with 4-1BB. Mol. Cancer Ther. 11:1062-1070. http://dx.doi.org/10.1158/1535-7163.MCT-11-0677
54. Watts, T.H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23:23-68. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115839
55. Wiersma, V.R., M. de Bruyn, W. Helfrich, and E. Bremer. 2013. Therapeutic potential of Galectin-9 in human disease. Med. Res. Rev. 33:E102-E126. http://dx.doi.org/10.1002/med.20249
56. Wilson, N.S., B. Yang, A. Yang, S. Loeser, S. Marsters, D. Lawrence, Y. Li, R. Pitti, K. Totpal, S. Yee, et al. 2011. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 19:101-113. http://dx.doi.org/10.1016/j.ccr.2010.11.012
57. Won, E.Y., K. Cha, J.S. Byun, D.U. Kim, S. Shin, B. Ahn, Y.H. Kim, A.J. Rice, T. Walz, B.S. Kwon, and H.S. Cho. 2010. The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily. J. Biol. Chem. 285:9202-9210. http://dx.doi .org/10.1074/jbc.M109.084442
58. Zhou, Z., X. Song, A. Berezov, G. Zhang, Y. Li, H. Zhang, R. Murali, B. Li, and M.I. Greene. 2008. Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc. Natl. Acad. Sci. USA. 105:5465-5470. http://dx.doi.org/10.1073/pnas.0711350105
59. Zhu, C., A.C. Anderson, A. Schubart, H. Xiong, J. Imitola, S.J. Khoury, X.X. Zheng, T.B. Strom, and V.K. Kuchroo. 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6:1245-1252. http://dx.doi.org/10.1038/ni1271